Navigation Links
What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Date:2/17/2009

PPAR- gamma is manifested in a variety of tissues and cancer cells and the ligands that activate PPAR- PPAR- are currently being studied as a novel treatment. The PPAR-gamma ligand generally decreases the survival rate of cancer cells via differentiation, apoptotic induction, and changes in genes or proteins associated with entrance into the G1/S phase. There have been some reports suggesting that stomach cancer cells manifest PPAR- gamma and are suppressed by the PPAR- gamma ligand. Recently, another report has shown that troglitazone, the ligand of PPAR- gamma , may prove useful in preventive medicine, and this effect is dependent on PPAR- gamma .

A research article to be published in volume 15 on January 21, 2009 in the World Journal of Gastroenterology addresses this point. A research team led by Professor DH Kim from the Medical Research Institute, Pusan National University Hospital, Korea found that the reaction of the PPAR- gamma agonist pathway on PPAR- gamma , troglitazone, suppresses the proliferation of colon cancer cells, and induces apoptosis, and expression of the growth response-1 gene in early phase. These processes are activated downstream of the suppression one by one via a PPAR- gamma -independent pathway. Moreover, an inductive chemical compound associated with CDDO causes PPAR- gamma -dependent caveolin expression and a PPAR- gamma -independent induction of the apoptosis reaction.

This report shows that ciglitazone and troglitazone suppress the proliferation of stomach cancer cells via the arrest of G1 phase. The arrest of G1 phase was reported in colon cancer cells via activation of PPAR- gamma. Also, each of the stomach cancer cell types which demonstrated p53 mutations were suppressed more strongly by troglitazone than by ciglitazone, and this effect was more evident in the SNU-668 than in the SNU-216 cells. SNU-668 cells demonstrated p53 and ras mutations, and it will be necessary in future studies to clarify the relationship between these results and the underlying mechanisms. This means that the concentrations of troglitazone that are used clinically suppress the growth of stomach cancer cells, and this may be used as a method to target therapy of gastric cancer.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Escape cancer, but age sooner? The dark side of the tumor suppressing process
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Cancer-Suppressing Gene Tied to Female Fertility
4. Study shows suppressing herpes virus may reduce infectiousness of HIV
5. MU researcher demonstrates non-traditional therapy is effective as pain management
6. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
7. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
8. Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA
9. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
10. Potential atherosclerosis drug exhibits no harmful side-effects in liver
11. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan ... dentistry options for its patients on Long Island, New York. , Holistic ... being, and is one of the biggest trends in dentistry today. , ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve ... decision process. As a result, labels need to deliver simple, transparent and clear ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Clinical Integration company, announced today that its iClinic V12.2 solution has achieved approval ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a ...
(Date:5/23/2017)... NY (PRWEB) , ... May 23, 2017 , ... ... in the pharmaceutical and medical device sectors, today announced the winners of its ... • Entrepreneurs) represent the most influential people in the healthcare industry today. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a national ... category winner, has named Daniel P. Bullington as chief technology officer. , “i2i ... and product offerings,” says Justin Neece, president. “Daniel is an excellent fit for ...
Breaking Medicine News(10 mins):
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
(Date:5/2/2017)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... Med Tech Reimbursement Consulting AB that allows for ... Consulting AB,s proprietary market analyses through the MarketResearch.com website. ... the world easy access to complete product descriptions and ...
(Date:5/2/2017)... CORALVILLE, Iowa , May 2, 2017 /PRNewswire/ ... innovative, patient-centric radiotherapy solutions, announced today that ... has been with CIVCO since 2012 and has ... line management, senior vice president and general manager, ... manager. "I am extremely proud of ...
Breaking Medicine Technology: